| Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study BA Fisher, A Szanto, WF Ng, M Bombardieri, MG Posch, AS Papas, ... The Lancet Rheumatology 2 (3), e142-e152, 2020 | 113 | 2020 |
| World workshop on oral medicine VII: Burning mouth syndrome: A systematic review of disease definitions and diagnostic criteria utilized in randomized clinical trials A Ariyawardana, M Chmieliauskaite, AM Farag, R Albuquerque, ... Oral Diseases 25, 141-156, 2019 | 61 | 2019 |
| The Novel Anti-CD40 Monoclonal Antibody CFZ533 Shows Beneficial Effects in Patients with Primary Sjogren's Syndrome: A Phase IIa Double-Blind, PlaceboControlled Randomized Trial B Fisher, M Zeher, WF Ng, M Bombardieri, M Posch, AS Papas, AM Farag, ... Arthritis & Rheumatology 69, 2017 | 45 | 2017 |
| Oral immune‐related adverse events associated with PD‐1 inhibitor therapy: A case series MA Shazib, SB Woo, H Sroussi, I Carvo, N Treister, A Farag, J Schoenfeld, ... Oral diseases 26 (2), 325-333, 2020 | 40 | 2020 |
| Oral and maxillofacial pathology C Allen, B Neville, D Damm, J Bouquot United States: Saunders, 2002 | 32 | 2002 |
| Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation AM Farag, C Holliday, J Cimmino, T Roomian, A Papas Oral diseases 25 (8), 1937-1944, 2019 | 31 | 2019 |
| World Workshop in Oral Medicine VII: Reporting of IMMPACT‐recommended outcome domains in randomized controlled trials of burning mouth syndrome: A systematic review AM Farag, R Albuquerque, A Ariyawardana, M Chmieliauskaite, ... Oral Diseases 25, 122-140, 2019 | 29 | 2019 |
| The effectiveness of acupuncture in the management of persistent regional myofascial head and neck pain: A systematic review and meta-analysis AM Farag, A Malacarne, SE Pagni, GE Maloney Complementary Therapies in Medicine 49, 102297, 2020 | 21 | 2020 |
| Head and neck manifestations of endocrine disorders AM Farag Atlas of the Oral and Maxillofacial Surgery Clinics of North America 25 (2 …, 2017 | 18 | 2017 |
| Consensus agreement to rename burning mouth syndrome and improve International Classification of Diseases-11 disease criteria: an international Delphi study M Chmieliauskaite, EA Stelson, JB Epstein, GD Klasser, A Farag, B Carey, ... Pain 162 (10), 2548-2557, 2021 | 16 | 2021 |
| Is burning mouth a syndrome or a disorder? A commentary CS Miller, AM Farag, M Chmieliauskaite, A Ariyawardana, R Albuquerque, ... Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 127 (5), 361-363, 2019 | 16 | 2019 |
| WWOM VII: Effectiveness of systemic pharmacotherapeutic interventions in the management of BMS: A systematic review and meta‐analysis AM Farag, M Kuten‐Shorrer, Z Natto, A Ariyawardana, LM Mejia, ... Oral Diseases 29 (2), 343-368, 2023 | 13 | 2023 |
| A randomized controlled study to evaluate an experimental moisturizing mouthwash formulation in participants experiencing dry mouth symptoms A Jose, ML Singh, B Magnuson, A Farag, R Varghese, A Papas Oral surgery, oral medicine, oral pathology and oral radiology 126 (3), 231 …, 2018 | 12 | 2018 |
| IMMPACT-recommended outcome measures and tools of assessment in burning mouth syndrome RCTs: an international Delphi survey protocol B Carey, AM Farag, C Nasri-Heir, GD Klasser, A Ariyawardana, ... Trials 21, 1-6, 2020 | 11 | 2020 |
| World Workshop on Oral Medicine VIII: Development of a core outcome set for oral lichen planus: a systematic review of outcome domains RM López-Pintor, M Diniz-Freitas, SSK Ramesh, JA Valdéz, H Dan, ... Oral surgery, oral medicine, oral pathology and oral radiology 135 (6), 772-780, 2023 | 9 | 2023 |
| Chronic oral lesions AF Bukhari, AM Farag, NS Treister Dermatologic Clinics 38 (4), 451-466, 2020 | 9 | 2020 |
| Salivary glands ultrasonography as a diagnostic aid in Sjögren syndrome: A prospective pilot investigation AF Bukhari, A Farag, A Papas, R Ganguly, H Campos, A Ramesh Oral surgery, oral medicine, oral pathology and oral radiology 132 (2), 172-181, 2021 | 7 | 2021 |
| FRI0174 Subcutaneous dosing of the novel anti-CD40 antibody iscalimab achieves target drug exposure and clinical efficacy in primary Sjögren’s syndrome; results of a phase IIa … B Fisher, A Szántó, WF Ng, M Bombardieri, M Posch, A Papas, A Farag, ... Annals of the Rheumatic Diseases 78 (Suppl 2), 760-761, 2019 | 6 | 2019 |
| Utilizing the concept of geste antagoniste for conservative management of oro-mandibular tardive dyskinesia: a case report and mini-review AM Farag, RW Mier, LP Correa CRANIO® 34 (5), 338-342, 2016 | 6 | 2016 |
| WWOM VII: Effectiveness of topical interventions in the management of burning mouth syndrome: A systematic review S Goncalves, B Carey, AM Farag, M Kuten‐Shorrer, ZS Natto, ... Oral Diseases 29 (8), 3016-3033, 2023 | 5 | 2023 |
